[
  {
    "ts": null,
    "headline": "Zoetis Faces Librela Safety Reviews While Valuation Signals Potential Upside",
    "summary": "Zoetis (NYSE:ZTS) is facing increased regulatory scrutiny of its monoclonal antibody pain drugs, with the FDA updating safety warnings for Librela. Regulators in multiple markets are reviewing adverse event reports linked to osteoarthritis pain therapies used in companion animals. At the same time, Zoetis is rolling out new pain products internationally after recent approvals in key regions. The company is also expanding its animal health diagnostics footprint through acquisitions and...",
    "url": "https://finnhub.io/api/news?id=44fbbdccabfb6cbd347849cafce0f209c617f28315253741b476536774599f1b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771002748,
      "headline": "Zoetis Faces Librela Safety Reviews While Valuation Signals Potential Upside",
      "id": 139086718,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ZTS",
      "source": "Yahoo",
      "summary": "Zoetis (NYSE:ZTS) is facing increased regulatory scrutiny of its monoclonal antibody pain drugs, with the FDA updating safety warnings for Librela. Regulators in multiple markets are reviewing adverse event reports linked to osteoarthritis pain therapies used in companion animals. At the same time, Zoetis is rolling out new pain products internationally after recent approvals in key regions. The company is also expanding its animal health diagnostics footprint through acquisitions and...",
      "url": "https://finnhub.io/api/news?id=44fbbdccabfb6cbd347849cafce0f209c617f28315253741b476536774599f1b"
    }
  },
  {
    "ts": null,
    "headline": "Zoetis Q4 Earnings Call Highlights",
    "summary": "Zoetis (NYSE:ZTS) executives said the company delivered organic operational growth in 2025 despite a “dynamic operating environment” marked by macroeconomic pressure on pet owners and a more competitive landscape in key companion animal categories. Management also outlined 2026 guidance calling for",
    "url": "https://finnhub.io/api/news?id=b42a64847e3037eddc3226f5f4f8b947c2abbe89cb319c0e8bc637c55cf149a2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770984797,
      "headline": "Zoetis Q4 Earnings Call Highlights",
      "id": 139081405,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ZTS",
      "source": "Yahoo",
      "summary": "Zoetis (NYSE:ZTS) executives said the company delivered organic operational growth in 2025 despite a “dynamic operating environment” marked by macroeconomic pressure on pet owners and a more competitive landscape in key companion animal categories. Management also outlined 2026 guidance calling for",
      "url": "https://finnhub.io/api/news?id=b42a64847e3037eddc3226f5f4f8b947c2abbe89cb319c0e8bc637c55cf149a2"
    }
  },
  {
    "ts": null,
    "headline": "Assessing Zoetis: Insights From 5 Financial Analysts",
    "summary": "",
    "url": "https://finnhub.io/api/news?id=ea6e0d04289a3b4df9311c4de52d3a93e5a7350cd0186c2e14120022d691097b",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770973226,
      "headline": "Assessing Zoetis: Insights From 5 Financial Analysts",
      "id": 139081665,
      "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/analyst_ratings_6.jpg?width=2048&height=1536",
      "related": "ZTS",
      "source": "Benzinga",
      "summary": " ",
      "url": "https://finnhub.io/api/news?id=ea6e0d04289a3b4df9311c4de52d3a93e5a7350cd0186c2e14120022d691097b"
    }
  },
  {
    "ts": null,
    "headline": "B of A Securities Maintains Neutral on Zoetis, Raises Price Target to $140",
    "summary": "B of A Securities  analyst Michael Ryskin   maintains Zoetis (NYSE:ZTS) with a Neutral and raises the price target from $135 to $140.",
    "url": "https://finnhub.io/api/news?id=d4231e357f4422092b68bf7311b7680647b0f46734677aa4085339db33c5a194",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770971038,
      "headline": "B of A Securities Maintains Neutral on Zoetis, Raises Price Target to $140",
      "id": 139081666,
      "image": "",
      "related": "ZTS",
      "source": "Benzinga",
      "summary": "B of A Securities  analyst Michael Ryskin   maintains Zoetis (NYSE:ZTS) with a Neutral and raises the price target from $135 to $140.",
      "url": "https://finnhub.io/api/news?id=d4231e357f4422092b68bf7311b7680647b0f46734677aa4085339db33c5a194"
    }
  },
  {
    "ts": null,
    "headline": "ZTS Q4 Deep Dive: Product Innovation and Competitive Pressures Shape Outlook",
    "summary": "Animal health company Zoetis (NYSE:ZTS) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 3% year on year to $2.39 billion. The company expects the full year’s revenue to be around $9.93 billion, close to analysts’ estimates. Its non-GAAP profit of $1.48 per share was 5.5% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=ecfbdd111f765f24a5298efd1ce72944d84a40f809bc669a5bf12a13213613bf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770960906,
      "headline": "ZTS Q4 Deep Dive: Product Innovation and Competitive Pressures Shape Outlook",
      "id": 139085210,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ZTS",
      "source": "Yahoo",
      "summary": "Animal health company Zoetis (NYSE:ZTS) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 3% year on year to $2.39 billion. The company expects the full year’s revenue to be around $9.93 billion, close to analysts’ estimates. Its non-GAAP profit of $1.48 per share was 5.5% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=ecfbdd111f765f24a5298efd1ce72944d84a40f809bc669a5bf12a13213613bf"
    }
  }
]